Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Authors:
Open Access
- 6 January 2021
- journal article
- review article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 14 (1) , 1-8
Abstract
Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we will summarize targeted drugs, such as hypomethylating agents, FLT3 inhibitors and isocitrate dehydrogenase inhibitors, as maintenance therapy post-transplantation in AML patients undergoing allo-HSCT.Keywords
Funding Information
- National Natural Science Foundation of China (No.81770190, No. 81970161)
- National Key Research and Development Programme of China (No. 2017YFA105500, 2017YFA105504)
- Natural Science Foundation of Guangdong Province (No. 2019A1515011924)
- Project of the Zhujiang Science & Technology Star of Guangzhou City (No.201806010029)
This publication has 61 references indexed in Scilit:
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 2013
- Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccineBlood Cancer Journal, 2013
- Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta‐analysisBritish Journal of Haematology, 2013
- Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignanciesLeukemia, 2013
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid LeukemiaJournal of Clinical Oncology, 2012
- High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responsesLeukemia, 2012
- Risk stratification–directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantationBlood, 2012
- Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndromeCancer, 2010
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- Low‐dose azacitidine after allogeneic stem cell transplantation for acute leukemiaCancer, 2009